Combination inhaled glucocorticoid/long-acting beta-agonist safety
نویسندگان
چکیده
منابع مشابه
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
BACKGROUND Combination therapy (inhaled corticosteroids and long-acting beta2-agonists) and tiotropium are both used in the treatment of chronic obstructive pulmonary disease (COPD). There is uncertainty about the relative benefits and harms of these treatments. OBJECTIVES To compare the relative effects of inhaled combination therapy and tiotropium on markers of exacerbations, symptoms, qual...
متن کاملTherapeutic Class Overview Inhaled Corticosteroid and Long-Acting β2-Agonist Combination Products
Therapeutic Class Overview/Summary: The combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) products include Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol) and Symbicort (budesonide/formoterol), with Dulera being the most recently Food and Drug Administration (FDA) approved product within the class. All of the products are FDA approved for the tr...
متن کاملSafety of long-acting beta-agonists.
Beta2-adrenoceptor agonists have been used as bronchodilators in the management of bronchial asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that beta2adrenoceptor agonist use may increase morbidity and mortality1. The long term beta-agonists, salmeterol and formeterol were introduced at the time of heightened concern about safety of beta2 agonist ...
متن کاملChanges to inhaled corticosteroid dose when initiating combination inhaler therapy in long-acting beta agonist naïve patients with asthma: a retrospective database analysis
Retrospective prescribing data were obtained from 46 general practice surgeries in NHS Scotland. Patients with asthma who were naïve to previous LABA therapy and initiated combination inhaler therapy in 2008-2009 were classified according to the ICS dose in their combination inhaler compared to the highest dose of ICS they received before initiation. Among the 685 patients (541 [79.0%] who had ...
متن کاملA smarter way to manage asthma with a combination of a long-acting β2-agonist and inhaled corticosteroid
Symbicort SMART(R) (Symbicort Maintenance and Reliever Therapy) represents a new and unique way of treating patients with moderate-to-severe asthma, ie, those patients who require combination treatment with an inhaled corticosteroid and a long-acting inhaled beta(2)-agonist. Symbicort SMART enables patients to use only one inhaler, the budesonide-formoterol combination inhaler, for both mainten...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Allergy, Asthma & Immunology
سال: 2018
ISSN: 1081-1206
DOI: 10.1016/j.anai.2018.07.032